To compare the efficacy and safety profile of topical ivermectin versus topical metronidazole in patients with side effects like red-raised or pus-filled lesions, redness, itching, burning sensation, etc due to long-term use of topical steroid on face in a tertiary care teaching hospital.

Efficacy and safety profile of topical ivermectin and topical metronidazole in steroid induced rosacea in tertiary care teaching hospital. - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/12/078264

Enrollment

120

Registered

2024-12-18

Start date

Unknown

Completion date

Unknown

Last updated

2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L718- Other rosacea

Interventions

Intervention1: Topical Ivermectin 1% cream: to apply once daily at night for 3 months Control Intervention1: Topical Metronidazole 2% gel: to apply once daily at night for 3 months

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of either sex, 18-65 years age, with steroid induced rosacea. 2. Patient is off topical steroids for at-least 2 weeks.

Exclusion criteria

Exclusion criteria: 1. Pregnant and Lactating Women. 2. Drug allergy. 3. Children less than 18 years 4. Patients with Autoimmune Connective Tissue disease. 5. Associated Acne patients

Design outcomes

Primary

Measure	Time frame
1.To compare the efficacy of 2 % metronidazole gel and 1% ivermectin cream in steroid induced rosacea.Timepoint: Patients will be followed up on 3th, 6th, 9th and 12th week	—

Secondary

Measure	Time frame
Study the safety profile of 2% metronidazole gel and 1% ivermectin cream.Timepoint: Patients will be followed up on 3th, 6th, 9th and 12th week	—

Countries

India

Contacts

Public ContactDr CHIRAG SAINI

Government Medical College Haldwani

chirags536@gmail.com7895560725

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026